Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Approval Sought for Belantamab Mafodotin Combos for R/R Multiple Myeloma in Japan

September 18th 2024

Japan’s Ministry of Health, Labour, and Welfare has accepted the NDA for belantamab mafodotin plus bortezomib/dexamethasone in relapsed/refractory myeloma.

FDA Grants RMAT Designation to P-BCMA-ALL01 for R/R Multiple Myeloma

September 17th 2024

The FDA has granted regenerative medicine advanced therapy designation to P-BCMA-ALL01 for relapsed/refractory multiple myeloma.

Belantamab Mafodotin Plus Vd Earns Breakthrough Therapy Designation in China for R/R Myeloma

September 17th 2024

China’s NMPA granted breakthrough therapy designation to belantamab mafodotin plus bortezomib and dexamethasone in relapsed/refractory myeloma.

Dr Banerjee on the Benefit of Bispecific Antibody Dose Reduction in Multiple Myeloma

September 16th 2024

Rahul Banerjee, MD, FACP, discusses clinical benefits derived when reducing the dosing of bispecific antibodies in the management of multiple myeloma.

Myeloma Molecular Profiling Reveals Unique Copy Number and Expression Subtypes

September 13th 2024

Findings from a molecular analysis of the CoMMpass study identified copy number and expression subtypes of high-risk, newly diagnosed multiple myeloma.

Dr Banerjee on the Impact of Dose Modification Studies in Multiple Myeloma

September 13th 2024

Rahul Banerjee, MD, FACP, discusses the clinical impact of dose modification studies on the treatment of patients with multiple myeloma.

CoMMpass Data Continue to Shape Understanding of Genomic Diversity in Multiple Myeloma

September 12th 2024

Sagar Lonial, MD, FACP, discusses how genetic data from the CoMMpass trial continue to affect the understanding of multiple myeloma.

Potential Novel Lab Monitoring & Key Takeaways for Heavily Pre-Treated R/R MM

September 11th 2024

The key opinion leaders provide essential insights and recommendations for community oncologists to enhance and optimize treatment strategies for their patients with relapsed/refractory multiple myeloma.

Challenges of Treatment Sequencing in Heavily Pre-Treated R/R MM: Expert Insights

September 11th 2024

The experts in relapsed/refractory multiple myeloma care outline their treatment sequencing strategies for patients who have already received T-cell engaging therapies.

Dr Lonial on Characterizing Multiple Myeloma Subtypes in the CoMMpass Study

September 10th 2024

Sagar Lonial, MD, FACP, discusses unique subtypes of multiple myeloma identified through the CoMMpass study.

Dr Lonial on Findings from the CoMMpass Trial in Multiple Myeloma

September 6th 2024

Sagar Lonial, MD, FACP, discusses findings from the CoMMpass trial, which identified high-risk genetic markers in patients with myeloma.

D-VRd Improves MRD-Negativity Rates in Newly Diagnosed, Transplant-Eligible Myeloma

September 6th 2024

D-VRd improved rates of MRD negativity and sustained MRD negativity vs VRd in transplant-eligible, newly diagnosed multiple myeloma.

FDA Approves Bortezomib Injectable for Multiple Myeloma and MCL

September 6th 2024

The FDA has approved a new presentation of bortezomib for subcutaneous or intravenous administration.

Clinical Insights on the Patient Presentation & Treatment Course

September 4th 2024

The panel shares their expert impressions of the case and deliberates on potential treatment strategies for the 53-year-old patient with heavily pre-treated multiple myeloma, considering his prior therapies and current clinical status.

Patient Profile: 53-Year-Old Man with Heavily Pre-Treated MM including T-cell Directed Therapy

September 4th 2024

The panel presents and analyzes a case study of a 53-year-old man with heavily pre-treated multiple myeloma, including chemotherapy – based therapy and prior T-cell directed therapy, to illustrate treatment considerations and challenges in advanced disease management.

Dr Arnulf on Managing Tumor Burden for Improved PFS With Ide-Cel in R/R Myeloma

September 4th 2024

Bertrand Arnulf, MD, PhD, discusses the importance of managing tumor burden for improved outcomes with ide-cel in relapsed/refractory multiple myeloma.

Growth in the Multiple Myeloma Treatment Armamentarium Diversifies Treatment Strategies

September 2nd 2024

Rahul Banerjee MD, FACP, discusses how he decides between treatment approaches across subsets of patients with multiple myeloma.

The OncFive: Top Oncology Articles for the Week of 8/25

August 31st 2024

Mirdametinib NDA gets priority review in NF1-associated plexiform neurofibromas, experts explore social media's evolving role in cancer care, and more.

Dr McCarthy on Neutrophil Activity in Multiple Myeloma

August 30th 2024

Philip McCarthy, MD, discusses a study of neutrophil gene signatures within focal lesions that are linked to progression-free survival in multiple myeloma.

Stepwise Approach Helps Ease the Integration of BiTEs Into Community Cancer Centers

August 29th 2024

Courtney Van Houzen, PharmD, discusses key factors to be aware of when implementing bispecific T-cell engager programs into the community setting.